Among the "Best of ASCO 2010" trials was the failed Phase III study with picoplatin, Poniard Pharmaceuticals Inc.'s new platinum chemotherapy against small cell lung cancer. South San Francisco-based Poniard trotted out details from the experiment to mixed reviews, and whatever else the news did, it may have put the low-valued firm - which has hired Leerink Swann to pursue options - in position for a big-pharma takeover. Read More
